Abstract:Glia are imperative in nearly every function of the nervous system, including neurotransmission, neuronal repair, development, immunity, and myelination. Recently, the reparative roles of glia in the central and peripheral nervous systems have been elucidated, suggesting a tremendous potential for these cells as novel treatments to central nervous system disorders. Glial cells often behave as 'double-edged swords' in neuroinflammation, ultimately deciding the life or death of resident cells. Compared to glia, neuronal cells have limited mobility, lack the ability to divide and self-renew, and are generally more delicate. Glia have been candidates for therapeutic use in many successful grafting studies, which have been largely focused on restoring myelin with Schwann cells, olfactory ensheathing glia, and oligodendrocytes with support from astrocytes. However, few therapeutics of this class have succeeded past clinical trials. Several tools and materials are being developed to understand and re-engineer these grafting concepts for greater success, such as extra cellular matrix-based scaffolds, bioactive peptides, biomolecular delivery systems, biomolecular discovery for neuroinflammatory mediation, composite microstructures such as artificial channels for cell trafficking, and graft enhanced electrical stimulation. Furthermore, advances in stem cell-derived cortical/cerebral organoid differentiation protocols have allowed for the generation of patient-derived glia comparable to those acquired from tissues requiring highly invasive procedures or are otherwise inaccessible. However, research on bioengineered tools that manipulate glial cells is nowhere near as comprehensive as that for systems of neurons and neural stem cells. This article explores the therapeutic potential of glia in transplantation with an emphasis on novel bioengineered tools for enhancement of their reparative properties. STATEMENT OF SIGNIFICANCE: Neural glia are responsible for a host of developmental, homeostatic, and reparative roles in the central nervous system but are often a major cause of tissue damage and cellular loss in insults and degenerative pathologies. Most glial grafts have employed Schwann cells for remyelination, but other glial with novel biomaterials have been employed, emphasizing their diverse functionality. Promising strategies have emerged, including neuroimmune mediation of glial scar tissues and facilitated migration and differentiation of stem cells for neural replacement. Herein, a comprehensive review of biomaterial tools for glia in transplantation is presented, highlighting Schwann cells, astrocytes, olfactory ensheating glia, oligodendrocytes, microglia, and ependymal cells.

Glial biomarkers in human central nervous system disease

Activation of Astrocytes in Neurodegenerative Diseases

Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases

Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases

Neurovascular unit, neuroinflammation and neurodegeneration markers in brain disorders

A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer's disease patients from controls

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Human Glial Cells as Innovative Targets for the Therapy of Central Nervous System Pathologies

Emerging Microglial Therapies and Targets in Clinical Trial

From Pathophysiology to Clinical Implications

Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative

Glial reactivity is linked to synaptic dysfunctionacross the aging and Alzheimer's disease spectrum

Major depressive disorder and anxiety disorders from the glial perspective: Etiological mechanisms, intervention and monitoring

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia

Glia in tissue engineering: From biomaterial tools to transplantation

Biomarkers for Alzheimer's disease: current status and prospects for the future

The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain

More than microglia: myeloid cells and biomarkers in neurodegeneration

Autoimmune central nervous system disorders: Antibody testing and its clinical utility

Biomarkers for Managing Neurodegenerative Diseases